Galectin Therapeutics (NASDAQ: GALT $3.80) GALT is our number 1 stock pick for August, 2018. After a fundamental analysis we conclude the scientific data is credible & compelling, GALT is … [Read more...] about GALT is Strong Buy: Oversold and Cancer Catalyst Imminent